Biomedical literature, made navigable
Discover articles through diseases, drugs, treatments, interventions, clinical instruments, institutions and funders extracted from the BMJ open corpus.
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsChoose an entity to see the articles in which it was identified.
… (13 (21%) specifically for Shigella); MSM living with HIV with shigellosis were significantly older (p<0.01), had fewer sex partners (p<0.…
…Background Significant calcification in a coronary chronic total occlusion (CTO) is associated with percutaneous coronary intervention (PC…
…en January 2018 and August 2021 when lesions were assessed with indigo carmine alone. Lesions were stained with crystal violet 0.05% for one m…
….Results COLO-COHORT data were available for 1959 participants. Colorectal neoplasia was present in 858 participants (43.8%). Advanced neoplasia and…
…ng to a prevalence of 3.5%. Conversely, among 159 patients with Plummer Vinson syndrome, celiac disease was diagnosed in 13 cases (8.2%). There were 10…
… ≥2, and inadequate response/intolerance (IR) to TNFa blockers, vedolizumab, ustekinumab, JAK inhibitors, or S1P receptor modulators (BIO/J…
…ilar era, where cost-effectiveness impacts therapeutic choices, filgotinib is an attractive option for UC. Whilst pivotal trial data and s…
…se results demonstrate increased levels of protease activity in IBD patients relative to HC. They also show higher levels in IBD pa…
…ngs provide mechanistic support for early or combination use of upadacitinib alongside corticosteroids in ASUC and strengthen the rationale …
…f depressive symptoms, a nurse-led service evaluation using the Patient Health Questionnaire-9 (PHQ-9) was conducted, self-completed by patients attending an …
…with inflammatory bowel disease (IBD) have an increased risk of colorectal cancer (CRC), and colonoscopic surveillance is recommended to detect …